Literature DB >> 2993897

Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

B Beutler, D Greenwald, J D Hulmes, M Chang, Y C Pan, J Mathison, R Ulevitch, A Cerami.   

Abstract

In mammals, several well-defined metabolic changes occur during infection, many of which are attributable to products of the reticuloendothelial system. Among these changes, a hypertriglyceridaemic state is frequently evident, resulting from defective triglyceride clearance, caused by systemic suppression of the enzyme lipoprotein lipase (LPL). We have found previously that macrophages secrete the hormone cachectin, which specifically suppresses LPL activity in cultured adipocytes (3T3-L1 cells). When originally purified from RAW 264.7 (mouse macrophage) cells, cachectin was shown to have a pI of 4.7, a subunit size of relative molecular mass (Mr) 17,000 and to form non-covalent multimers. A receptor for cachectin was identified on non-tumorigenic cultured cells and on normal mouse liver membranes. A new high-yield purification technique has enabled us to determine further details of the structure of mouse cachectin. We now report that a high degree of homology exists between the N-terminal sequence of mouse cachectin and the N-terminal sequence recently determined for human tumour necrosis factor (TNF). Purified cachectin also possesses potent TNF activity in vitro. These findings suggest that the 'cachectin' and 'TNF' activities of murine macrophage conditioned medium are attributable to a single protein, which modulates the metabolic activities of normal as well as neoplastic cells through interaction with specific high-affinity receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993897     DOI: 10.1038/316552a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  231 in total

Review 1.  TNF ligands and receptors--a matter of life and death.

Authors:  David J MacEwan
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Production of polyclonal antibodies to feline tumor necrosis factor.

Authors:  C M Otto; F Niagro; R A McGraw; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

3.  Effects of tumor necrosis factor alpha on sin nombre virus infection in vitro.

Authors:  S F Khaiboullina; D M Netski; P Krumpe; S C St Jeor
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  [Do antisense oligonucleotides improve viral immunopathology?].

Authors:  S Wasmuth; D Bauer; K P Steuhl; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

5.  Nobel Prize laureates pave the way for therapeutic advances in sepsis.

Authors:  Frédéric Pène; Jean-Paul Mira; Jean-Daniel Chiche
Journal:  Intensive Care Med       Date:  2011-12-06       Impact factor: 17.440

Review 6.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

7.  Critical role of the C-terminus in the biological activities of human tumour necrosis factor-alpha.

Authors:  K Gase; V G Korobko; H G Wisniewski; J Le; V N Dobrynin; S A Filippov; W Gutsche; Y N Maksimova; B Schlott; L N Shingarova
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

8.  Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes.

Authors:  R Zechner; T C Newman; B Sherry; A Cerami; J L Breslow
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

9.  Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.

Authors:  M Nagarkatti; P S Nagarkatti; A M Kaplan
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Effect of recombinant tumour necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi.

Authors:  C M Black; D M Israelski; Y Suzuki; J S Remington
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.